UBS Asset Management Americas Inc. lowered its position in Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 138,117 shares of the biopharmaceutical company’s stock after selling 4,468 shares during the period. UBS Asset Management Americas Inc. owned 0.56% of Intercept Pharmaceuticals worth $19,706,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the company. CENTRAL TRUST Co purchased a new position in Intercept Pharmaceuticals during the second quarter valued at $107,000. Legal & General Group Plc increased its position in Intercept Pharmaceuticals by 15.8% in the first quarter. Legal & General Group Plc now owns 1,144 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 156 shares in the last quarter. IBM Retirement Fund increased its position in Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 58 shares in the last quarter. BlackRock Inc. increased its position in Intercept Pharmaceuticals by 301.5% in the first quarter. BlackRock Inc. now owns 1,915 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 1,438 shares in the last quarter. Finally, Bbva Compass Bancshares Inc. increased its position in Intercept Pharmaceuticals by 5.4% in the second quarter. Bbva Compass Bancshares Inc. now owns 1,948 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 99 shares in the last quarter. 81.86% of the stock is owned by hedge funds and other institutional investors.

Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded up 0.66% during midday trading on Monday, reaching $158.23. The company’s stock had a trading volume of 194,152 shares. Intercept Pharmaceuticals Inc. has a 1-year low of $89.76 and a 1-year high of $217.99. The company’s 50-day moving average price is $159.41 and its 200 day moving average price is $145.77. The firm’s market capitalization is $3.91 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.69) by $0.55. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The business earned $5.52 million during the quarter, compared to analyst estimates of $1.72 million. During the same quarter last year, the firm earned ($1.99) earnings per share. The company’s revenue for the quarter was up 1140.4% compared to the same quarter last year. On average, equities research analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.31) earnings per share for the current year.

Several equities analysts have weighed in on the company. Wedbush reaffirmed a “buy” rating and issued a $239.00 target price on shares of Intercept Pharmaceuticals in a research report on Saturday, July 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $350.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 1st. Vetr downgraded Intercept Pharmaceuticals from a “buy” rating to a “hold” rating and set a $146.64 target price for the company. in a research report on Tuesday, May 31st. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Finally, Leerink Swann reaffirmed a “hold” rating and issued a $140.00 target price (down from $144.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 31st. Five analysts have rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $177.67.

In other news, insider Lisa Bright sold 246 shares of the stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $159.00, for a total value of $39,114.00. Following the completion of the sale, the insider now owns 18,460 shares in the company, valued at $2,935,140. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mark Pruzanski sold 714 shares of the stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total value of $103,608.54. The disclosure for this sale can be found here. 9.20% of the stock is owned by insiders.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.